DoseMeRx vs InsightRX
The precision dosing shortlist, and it is a genuine one because both compute a dose for drugs where getting it wrong causes kidney injury or treatment failure. InsightRX is the more inspectable: the population pharmacokinetic models it runs are published rather than proprietary, so a pharmacy can read the science behind the recommendation, and it holds certified Epic marketplace integration plus a published analysis of more than 168,000 treatment courses. DoseMeRx is the better designed at the bedside: it shows the pharmacist how well the model fits this patient's measured concentrations, which is the disclosure that tells you when to distrust the answer, and it publishes the clearest data residency statement in the category alongside HITRUST certification. Neither is FDA cleared, which is normal here and worth stating plainly, since the dose is computed by software no regulator has reviewed.
- The interface shows how well the model actually fits this patient's measured concentrations alongside the recommended dose, which is the strongest oversight design in the category because it lets a pharmacist see when the model is struggling rather than only what it concluded.
- The residency and stewardship disclosure is the most specific here, naming the cloud provider and the region, and stating what happens to patient data, where competitors publish nothing at all.
- HITRUST certification is held and the company states it is the only Bayesian dosing platform carrying it, which is a checkable competitive claim rather than a badge, alongside the widest geographic footprint in the segment.
- The model stack is the most inspectable in this index. The population pharmacokinetic models are named and published rather than proprietary, so a pharmacy department can read the literature behind the dose the software proposes.
- Certified integration rather than asserted, with applications fully certified in the Epic marketplace and automatic import limited to the data the dosing calculation actually needs rather than bulk extraction.
- A published analysis of more than 168,000 treatment courses, which is the strongest governance artifact in the lane and the closest thing to post deployment monitoring anyone here has produced.
Side by Side
| Axis | D DoseMeRx |
I InsightRX |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither vendor holds a United States device clearance and neither claims one, which is the settled position for therapeutic drug monitoring software generally, but it means the dose these products compute is not reviewed by a regulator. Neither publishes pricing.
The independent head to head comparison in this segment, published in Pharmacotherapy, included both platforms and did not find them equivalent across every drug and scenario tested, so ask each vendor how it performed for the specific agents your service uses rather than in aggregate. DoseMeRx publishes no performance reporting by age, sex, race, renal function band or body habitus, and neither vendor publishes a bias assessment.